REMARKS

It is respectfully submitted that the amendments submitted herewith function only to insert the sequence listing and appropriate sequence identifiers into the text of the present application to comply with 37 C.F.R. §1.821 to 1.825. These amendments are made without prejudice, without admission, without surrender of subject matter, and without any intention of creating any estoppel as to equivalents.

It is respectfully submitted that the Sequence Listing conforms to the requirements of 37 C.F.R. §1.823(b). The Statements required by 37 C.F.R §1.821(f) and (g) are set forth below.

Pursuant to 37 C.F.R. §1.821 (g), the undersigned hereby states that this submission, filed in accordance with 37 C.F.R. §1.821 (g), does not contain new matter.

Pursuant to 37 C.F.R. §1.821 (f), the undersigned hereby states that the content of the paper and computer readable copies of the Sequence Listing submitted in accordance with 37 C.F.R. §1.821 (c) and (e), respectively, are the same.

CONCLUSION

In view of the amendments, remarks and enclosures herein, it is respectfully submitted that the application now complies with all requirements set forth in the Notice. Accordingly, reconsideration and withdrawal of the Notice to Comply with Requirements for Patent Applications Containing Nucleotide Sequence and/or Amino Acid Sequence Disclosures ("Notice to Comply") is respectfully requested.

Respectfully submitted,

FROMMER LAWRENCE & HAUG LLP
Attorneys for the Applicant

By: 

Thomas J. Kowalski
Reg. No. 32,147
Angela M. Nigro
Reg. No. 51,107
(212) 588-0800

Enclosures: Paper and Diskette copies of Sequence Listing
Copy of Notice to Response To Notice To Comply
Return receipt postcard

"VERSION WITH MARKINGS TO SHOW CHANGES MADE"

Page 10, line 21:

Figure 2: Polynucleotide sequence of complete cDNA encoding human CTLA-4 and polypeptide sequence of the VLD of human CTLA-4. (SEQ ID NO: 57-58)

Page 10, line 30:

Figure 4: Schematic representation of the somatostatin polypeptide. Somatostatin (somatotropin release-inhibiting factor SRIF) is a cyclic 14-amino acid polypeptide. The cyclic nature is provided by a disulphide linkage between the cysteine residues at positions 3 and 14. The four residues which constitute the tip of the loop (Phe-Trp-Lys-Thr) are implicated in binding to members of the somatostatin receptor family. (SEQ ID NO: 139)

Page 27, line 1:

Table 4 CDR1 and CDR3 Inserts from a Representative Series of Library 2 Clones (SEQ ID NOS: 102-142)

CLONE	CDR1	CDR3
3M-2	ND1	LPSSTDTRAYS (SEQ ID NO: 102)
3M-3	QESGGRPG (SEQ ID NO:103)	LPRGPPLLSL (SEQ ID NO: 104)
3M-5	SPGRCLN (SEQ ID NO: 105)	ND
3M-6	EWKREHGG (SEQ ID NO: 106)	LCPGACGCVY (SEQ ID NO: 107)
3M-7	NSGENEGG (SEQ ID NO: 108)	ND
3M-11	DKPVTKSG (SEQ ID NO: 109)	ND
3M-17	SPGACPE (SEQ ID NO: 110)	ND
3M-18	SPGKCDQ (SEQ ID NO: 111)	ND
3M-19	SPGMCAR (SEQ ID NO: 112)	LMYPPPYYL (SEQ ID NO: 63)
3M-20	ND	PFLFLPCEFFF (SEQ ID NO: 113)
3N-1	WTLGHHKLCEG (SEQ ID NO: 114)	LTFCLLALCS (SEQ ID NO: 115)
3N-2	SPGECYG (SEQ ID NO: 116)	SWLSTTXCLSSCS (SEQ ID NO: 117)
3N-3	SPG[*]ECQD (SEQ ID NO: 118)	LLGSLLSCFASLS (SEQ ID NO: 119)
3N-4	SP[*]ECQD (SEQ ID NO: 142)	SPGSLLSCFASXS (SEQ ID NO: 120)
3N-5	SPGRCTD (SEQ ID NO: 121)	VICHSSVCLSD/EVC (SEQ ID NOS: 122-123)

CLONE	CDR1	CDR3
3N-6	ND	DLPSYLACSI (SEQ ID NO: 124)
3N-7	SPGRCDA (SEQ ID NO: 125)	ALCWDVFYCSFPSY (SEQ ID NO: 126)
3N-8	ELFGHARYCKG (SEQ ID NO: 127)	VSITSPELCPVKVFD (SEQ ID NO: 128)
3N-9	SPGKVEN (SEQ ID NO: 129)	LFVPFVSP (SEQ ID NO: 130)
3N-12	SPGDLWV (SEQ ID NO: 131)	ESGLSPVSPCSLYSL (SEQ ID NO: 132)
3N-13	TSANGPYG (SEQ ID NO: 133)	PWAYRFLAVL (SEQ ID NO: 134)
3N-14	RKTREKYG (SEQ ID NO: 135)	ELMYPPPYYLGI (SEQ ID NO: 136)
3N-15	SPGQELT (SEQ ID NO: 137)	ELFFLLYAPCYLFQR (SEQ ID NO: 138)

ND: Not Done

*: UAG termination codon